Caring for someone with schizophrenia or bipolar disorder? The FDA just approved the first treatment for sudden agitation that can be taken at home
Igalmi, a thin film that dissolves under the tongue, was cleared only for use with a health care worker present. Up to 21% of agitation episodes now end in an emergency room or hospital, its maker says.
Adults with schizophrenia, schizoaffective disorder or bipolar disorder can now treat a sudden episode of agitation at home. The U.S. Food and Drug Administration approved Igalmi, a prescription film placed under the tongue or between the lower lip and gum, for at-home use, drugmaker Teva announced Monday. Teva says it is the first FDA-approved treatment for agitation tied to these conditions that patients can take outside a clinic or hospital.
Agitation can mean feelings of tension, restlessness and a burst of activity. It affects 25% to 40% of people with these conditions and can escalate quickly; up to 21% of episodes end with an emergency room visit or a hospital stay, according to Teva. Until now, treatments generally had to be given in a health care setting or with a health care worker watching.
What it means for patients and families
Patients and caregivers can ask the patient’s psychiatrist or other prescriber whether Igalmi makes sense for them. It isn’t available for home use yet: Teva says it will announce its plans for selling the at-home version later, and it has not said what it will cost.
The drug can lower blood pressure and slow the heart rate, which can cause fainting or falls. Teva’s safety information tells patients to drink fluids, sit or lie down after taking it, and get up slowly. The most common side effects at home were sleepiness, dry mouth, dizziness and numbness or tingling in the mouth. Tell the prescriber about heart problems, a slow heart rate, low or long-term high blood pressure, fainting, diabetes, liver problems, low potassium or magnesium, or being 65 or older, and about other medicines, especially blood pressure drugs, opioids or sleeping pills. It is not known whether Igalmi is safe or effective in children.
How it works
Igalmi’s active ingredient is dexmedetomidine, which acts on alpha-2 receptors, switches in the brain and nerves that help turn down the body’s stress response. The film delivers the drug through the lining of the mouth instead of a shot or a pill that has to be swallowed.
The studies
The FDA first approved Igalmi for use under a health care worker’s supervision. In those earlier SERENITY I and II trials, patients’ scores on a standard agitation scale fell about 9.6 points two hours after a dose, compared with about 4.9 points on a placebo, or dummy treatment, Teva says.
The new at-home approval rests on a 12-week trial in which neither patients nor researchers knew who got the drug or a placebo. Its main goal was to check safety, not effectiveness: 102 patients used Igalmi to treat 1,160 agitation episodes, side effects stayed about the same with repeat doses, and no one quit because of side effects, Teva said. Teva, a global drugmaker whose U.S. arm is based in Parsippany, N.J., acquired the drug in late October 2026.